Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2012

01-02-2012 | Letter to the Editor

Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide

Author: Masaki Iino

Published in: International Journal of Hematology | Issue 2/2012

Login to get access

Excerpt

The immunomodulatory drugs (IMiDs), thalidomide and lenalidomide, and the proteasome inhibitor bortezomib have recently been indicated for multiple myeloma treatment. Although pulmonary complications associated with bortezomib are widely known [1], those of IMiDs are thought to be rare. We present a multiple myeloma patient treated with bortezomib, who subsequently developed interstitial pneumonitis (IP) after treatments with both thalidomide and lenalidomide. …
Literature
1.
Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492–4.PubMedCrossRef
2.
Iguchi T, Sakoda M, Chen CK, Yokoyama K, Hattori Y, Ikeda Y, et al. Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma. Rinsyo Ketsueki. 2004;45:1064–6.
3.
Onozawa M, Hashino S, Sogabe S, Haneda M, Horimoto H, Izumiyama K, et al. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis. J Clin Oncol. 2005;23:2425–6.PubMedCrossRef
4.
Sasaki M, Isobe Y, Tsukune Y, Kawahara S, Hamano Y, Ando J, et al. Thalidomide may induce interstitial pneumonia preferentially in Japanese patients. Eur J Haematol. 2009;82:73–4.PubMedCrossRef
5.
Thornburg A, Abonour R, Smith P, Knox K, Twigg HL. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. Chest. 2007;131:1572–4.PubMedCrossRef
6.
Lerch E, Gyorik S, Feilichenfeldt J, Mazzucchelli L, Quadri F. A case of lenalidomide-induced hypersensitivity pneumonitis. Onkologie. 2010;33:249–52.PubMedCrossRef
7.
Chen Y, Kiatsimkul P, Nugent K, Raj R. Lenalidomide-induced interstitial lung disease. Pharmacotherapy. 2010;30:325.PubMedCrossRef
8.
Pretz J, Medeiros BC. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: no recurrence with subsequent lenalidomide therapy. Am J Hematol. 2009;84:698–9.PubMedCrossRef
9.
Sakai M, Kubota T, Kuwayama Y, Ikezoe T, Yokoyama A. Diffuse alveolar hemorrhage associated with lenalidomide. Int J Hematol. 2011;93:830–1.PubMedCrossRef
10.
Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Ocampo CJ, et al. Amino-substituted thalidomide analogues; potent inhibitors of TNF-alfa production. Bioorg Med Chem Lett. 1999;9:1625–30.PubMedCrossRef
Metadata
Title
Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide
Author
Masaki Iino
Publication date
01-02-2012
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0997-2

Other articles of this Issue 2/2012

International Journal of Hematology 2/2012 Go to the issue

Case Report

Epstein–Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma

Original Article

Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

Original Article

The effect of iron overload and chelation on erythroid differentiation

Progress in Hematology

New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis

Case Report

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

Case Report

A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits